Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.

ABSTRACT:

Background

Major depressive disorder (MDD) constitutes an important public health problem, as it is highly prevalent in the industrialized world and it is associated with substantial economic consequences for patients, health care providers, insurance and social security organizations and employers. To conduct an economic evaluation comparing agomelatine with other commonly used alternatives for treating patients with major depressive disorder (MDD) in Greece.

Methods

An existing international Markov model designed to evaluate the cost-effectiveness of agomelatine was adapted to the Greek setting. It reflects six different health states, in which patients may move on a monthly basis. The analysis was undertaken from a societal perspective. Transition probabilities, utilities

SUBMITTER: Maniadakis N 

PROVIDER: S-EPMC3654993 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature